MedTrace Logo

A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

NCT04041011 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-06-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of SHR-1316 in combination with Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

Conditions

Interventions

DRUG

1.Experimental: A (Part 1): Fluzoparib and SHR -1316

1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

DRUG

2.Experimental: B (Part 1): Fluzoparib and SHR -1316

2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

DRUG

3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion

3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-17
Primary Completion
2021-04-23
Completion
2021-04-23

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04041011 on ClinicalTrials.gov